According to the European Society of Cardiology (ESC) guidelines, iron deficiency (ID) in patients with heart failure (HF) is defined as ferritin < 100 μg/l (absolute ID) or ferritin 100–300 μg/l combined with transferrin saturation (TSAT) < 20% (functional ID) [1]. ID is as highly prevalent is the chronic HF population as 30–79% [2]. Nevertheless, in patients with HF with preserved ejection fraction (HFpEF) ID is less studied: according to the meta-analysis by Beale et al. it is estimated as 59% in these subjects [3]. The ESC guidelines recommend (IC) that all patients with symptomatic chronic HF undergo screening for ID [1]. Since ID and HF share symptoms such as fatigue and dyspnoea, in HF patients ID is often underdiagnosed and not corrected. Indeed, only a dedicated blood sample establishes the diagnosis. Ferric carboxymaltose (FCM) is the most studied compound in HF and it is the only iron supplementation recommended by the ESC guidelines [1]. To the best of our knowledge no data have been published so far on the use of FCM in patients with HFpEF.
Cosentino ER, C.A. (2021). Iron deficiency correction in heart failure patients with preserved ejection fraction: a case series study. ARCHIVES OF MEDICAL SCIENCE, 17(4), 1137-1139 [10.5114/aoms/136068].
Iron deficiency correction in heart failure patients with preserved ejection fraction: a case series study.
Cicero AFGSecondo
Conceptualization
;Borghi CUltimo
Supervision
2021
Abstract
According to the European Society of Cardiology (ESC) guidelines, iron deficiency (ID) in patients with heart failure (HF) is defined as ferritin < 100 μg/l (absolute ID) or ferritin 100–300 μg/l combined with transferrin saturation (TSAT) < 20% (functional ID) [1]. ID is as highly prevalent is the chronic HF population as 30–79% [2]. Nevertheless, in patients with HF with preserved ejection fraction (HFpEF) ID is less studied: according to the meta-analysis by Beale et al. it is estimated as 59% in these subjects [3]. The ESC guidelines recommend (IC) that all patients with symptomatic chronic HF undergo screening for ID [1]. Since ID and HF share symptoms such as fatigue and dyspnoea, in HF patients ID is often underdiagnosed and not corrected. Indeed, only a dedicated blood sample establishes the diagnosis. Ferric carboxymaltose (FCM) is the most studied compound in HF and it is the only iron supplementation recommended by the ESC guidelines [1]. To the best of our knowledge no data have been published so far on the use of FCM in patients with HFpEF.File | Dimensione | Formato | |
---|---|---|---|
Cosentino ER_Iron deficiency_Arch Med Sci_2021.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Condividi allo stesso modo (CCBYNCSA)
Dimensione
49.49 kB
Formato
Adobe PDF
|
49.49 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.